LANGER ROBERT
Known title: DirectorCIK: 0001239757
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Moderna faces stock dip amid cancer vaccine news and cash position. Recent articles note that Moderna holds a large cash reserve while advancing a deep cancer pipeline. A Phase 3 trial of its cancer vaccine reported positive results, which could broaden the company's product base. At the same time, the stock has fallen sharply, reflecting broader weakness in biotech and a pause in the recent rally. The decline occurs despite the cash strength and analyst price targets that remain well above current levels.
Transaction History
| SEER | ▲ Buy | Grant | 16,500 | $0 | 7/28/2026 | View on chart |
| SEER | ▲ Buy | Grant | 20,500 | $0 | 7/7/2025 | View on chart |
| SEER | ▲ Buy | Grant | 58,178 | $0 | 6/12/2024 | View on chart |
| SEER | ▲ Buy | Grant | 23,443 | $0 | 6/14/2023 | View on chart |
| SEER | ▲ Buy | Grant | 9,945 | $0 | 6/15/2022 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 703 | $0 | 4/28/2022 | View on chart |
| SEER | ▼ Sell | Other | 327,102 | — | 1/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced
Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced. Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.